An endoscopic treatment tool, includes an elongated member having a distal end and a proximal end; a braid disposed between the distal end and the proximal end of the elongated member; a distal indicator disposed on the elongated member between a distal end and a proximal end of the braid, the distal indicator extending along a longitudinal axis of the elongated member; a proximal indicator disposed between the distal end and the proximal end of the braid on the elongated member at a more proximal side of the elongated member than the distal indicator, the proximal indicator extending along the longitudinal axis; and a pre-curved shape portion formed in a curved shape, wherein each of the distal indicator and the proximal indicator has a width less than half of an outer circumferential surface of the elongated member in a circumferential direction of the elongated member, respectively.

A method of performing bariatric surgery using a robotic surgical system includes positioning a gastrectomy device in a selected location in a stomach; applying an adherent material to the stomach along a desired transection line; and cutting the stomach along the desired transection line delineated by the adherent material.

A papillotome for percutaneous endoscopic gastrostomy including a front opening located in a free end region of a catheter and at the outlet of a first lumen, a rear opening further from a free end than the front opening and connects the first lumen to the outside, and a cutting wire located in the first lumen in an axially displaceable manner and extends through the front opening and the rear opening and is located on the outside between the front opening and the rear opening. When the cutting wire is tensioned, the free end region is deformed in an arc shape and the cutting wire forms a transversely extending cutting edge between the front opening and the rear opening. The front opening is arranged at a distance of at least 3 mm from the free end. A projection is formed between the free end and the front opening. A cutting tip is formed at the free end of the catheter. The cutting tip is connected to the cutting wire and forms the foremost end of the papillotome.

An electrosurgical apparatus for treating fluid-filled biological growths by replacing the fluid within the growth with a substance that assists in delivering treatment energy. The treatment energy may be microwave energy or may be thermal energy derived from microwave energy. The apparatus comprises an instrument having a radiating tip portion, and a fluid delivery mechanism for transporting fluid to and from a treatment zone located around the radiating tip portion. The fluid delivery mechanism comprises a rigid insertion element arranged to extend into the treatment zone, whereby fluid can be aspirated from the treatment zone, and a substance injected into the treatment zone to replace the aspirated fluid. The injected substance has dielectric properties selected to facilitate uniform delivery of treatment energy to biological tissue in the treatment zone.

A medical device system includes an insertion device and a medical device. The insertion device includes an insertion device handle, including a port on a handle body. The insertion device also includes an insertion device shaft extending from the insertion device handle. The insertion device shaft includes a working channel connected to the port. The medical device includes a medical device handle, including a movable handle portion and a stationary handle portion. The movable handle portion includes a ball portion movably positioned within a cavity in the stationary handle portion. The medical device also includes a medical device shaft. The medical device shaft is configured to be delivered through the port in the insertion device handle and through the working channel in the insertion device shaft. Movement of the movable handle portion relative to the stationary handle portion controls movement of a distal portion of the medical device shaft.

An embodiment of the invention may include a medical device. The medical device may include a flexible tube, an elongate member configured to cut tissue and extend from the flexible tube, and a cauterizing member configured to cauterize tissue and to move relative to the elongate member and the flexible tube. The cauterizing member may substantially surround at least a portion of the elongate member.

Methods of treating and preventing cancer are provided. In some instances, the method comprises delivering radioactive particles to an organ of the subject, wherein the organ contains a tumor, applying alternating electric fields to the organ at a frequency of 50 kHz to 10 MHz (e.g., 50 kHz to 1 MHz or 80 to 500 kHz), and administering systemic cancer therapy to the subject.

A method for treating a tumor, comprising identifying a tumor as a colon cancer tumor and implanting in the tumor identified as a colon cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source with a suitable radon release rate and for a given duration, such that the source provides during the given duration a cumulated activity of released radon between 3.5 Mega becquerel (MBq) hour and 8.4 MBq hour, per centimeter length.

The present invention relates to a medical device for generating a plasma-activated liquid, a system for generating plasma-activated liquids comprising said device, and a method for generating a plasma-activated liquid. It also relates to a method for prophylaxis and treatment of postoperative adhesions.

Damaged, diseased, abnormal, obstructive, cancerous or undesired neural tissue treated by delivering specialized pulsed electric field (PEF) energy to target tissue areas. In some instances, the target tissue includes a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue. Most brain and spinal cord tumors develop from glial cells. These tumors are sometimes referred to as a group called gliomas. They arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). One difficulty in the treatment of gliomas is that they are behind the blood-brain barrier (BBB) and blood-tumor barrier (BTB) which leads to poor delivery of anti-cancer drugs or immune agents to the tumor-infiltrated brain. Devices, systems and methods are provided that treat the tumor directly, such as by ablation, and optionally transiently disrupt the BBB coupled with adjuvant antibody, biologic, or other pharmaceutical interventions.